SEC Form 4 · accession 0001209191-18-013680
CHIASMA, INC · CHMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Fitzpatrick
Officer — President and CEO · Director
Period of report
Feb 23, 2018
Accepted (ET)
Feb 26, 2018 · 9:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339469
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.52 | Feb 23, 2018 | A | 194,183 | A | — | Feb 23, 2028 | Common Stock | 194,183 | 194,183 | D |
| Stock Option (Right to Buy)F2 | $1.52 | Feb 23, 2018 | A | 67,967 | A | — | Feb 23, 2028 | Common Stock | 67,967 | 67,967 | D |
Explanation of responses
- F1The shares of Common Stock underlying the option will vest in quarterly installments over 4 years from the date of grant.
- F2The shares of Common Stock underlying the option will vest as follows: 40% of such award will be earned upon FDA acceptance of a new drug application (NDA) for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval.